LOGC:NSD- (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 8.18

Change

+0.02 (+0.25)%

Market Cap

N/A

Volume

0.29M
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
RPRX Royalty Pharma Plc

N/A

USD 18.35B
SMMT Summit Therapeutics PLC

N/A

USD 13.53B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing LOGC

TACK Fairlead Tactical Sector .. 7.97 % 0.00 %

N/A

USD 0.25B
GAL SPDR® SSgA Global Alloca.. 0.00 % 0.09 %

N/A

USD 0.25B
FISR SPDR® SSGA Fixed Income .. 0.00 % 0.00 %

N/A

USD 0.41B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.36% 81% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.36% 81% B- 84% B
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -96.03% 24% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.03% 24% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain 64.32% 83% B 91% A-
Dividend Return 64.32% 83% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 167.23% 26% F 13% F
Risk Adjusted Return 38.46% 91% A- 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.